Real-World Evidence of Eylea in the Treatment of NAMD

Prof. Daniel Barthelmes highlights the effectiveness of a proactive treat-and-extend regimen with aflibercept for neovascular AMD (nAMD), emphasising real-world data. Studies show that meaningful vision gains achieved in randomised trials, like ALTAIR, are mirrored in routine clinical practice. Real-world outcomes include vision improvements of 5.7–7.8 letters in the first year and sustained gains through Year 4. Injection frequencies decrease over time, with many patients achieving extended treatment intervals. These findings demonstrate that flexible treatment schedules significantly reduce the burden on patients and clinics while maintaining long-term visual benefits.